Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Leuk Res. 2010 Mar 23;34(8):969–973. doi: 10.1016/j.leukres.2010.02.033

Figure 1.

Figure 1

A) Schematic representation of the topographic distribution of the individual mutations in the TET2 (isoform A NM_0011270208) and ASXL1 proteins. Genomic sequencing revealed frame shift delC_1480Sfs and missense mutation V1718L in TET2 as well two missense mutations L1395V and Q1102D in ASXL1 gene. B) Frequency of TET2 and ASXL1 mutations, JAK2 V617F, MPL W515L and abnormal phospho-STAT5 activation in RARS-T patients. 2 monoallelic TET2 mutations were found in 9% of patients; 2 monoallelic ASXL1 mutations in 10%, 7 monoallelic and 1 biallelic JAK2 V617F mutations in 35%; MPL W515L mutations, 1 mono- and 2 biallelic, in 13%. Abnormal phospho-STAT5 activation was found in 63% of cases. The frequencies were calculated based on 22, 20, 23, 23, and 19 patients, respectively. Abbreviations: C-rich - cysteine-rich region; DSBH - double-stranded β helix; PEST, P - proline (P), glutamic acid (E), serine (S), and threonine (T); PHD - the plant homeodomain finger.